Similarly, IL-15-based agonists enhanced the NK cell response to Cetuximab-treated squamous cell carcinoma of head and neck (38) and colon cancer (31) and to Rituximab-treated B cell lymphoma cell lines (36). The gene discussed is IL15; the disease is B-cell non-Hodgkin lymphoma.